一个用免疫球蛋白治疗的肠胃异位症的红红斑症病例:一个病例报告
Adrienn N Bourkas1, Ryan Geng2, Matthew Sibbald3
1School of Medicine, Queen's University, Kingston, ON, Canada.
SAGE open medical case reports
|November 29, 2023
概括
本案例研究突出了一个罕见的自身免疫小纤维神经病变在一个18岁的女性. 静脉注射免疫球蛋白治疗有效地治疗了她的红红斑症和胃肠道疾病.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 一名18岁的女性出现了复杂的病史,包括亚托皮征程,超,和eosinophilic食道炎.
- 她被诊断出患有红色肌痛和胃肠异位症,疑似是由自身免疫性小纤维神经病变引起的.
研究的目的:
- 为了调查小纤维神经病变的潜在自身免疫病因,呈现出红色肌痛和胃肠异位症.
- 评估静脉注射免疫球蛋白治疗在管理这些复杂症状方面的疗效.
主要方法:
- 临床病例介绍和对自身免疫神经病变的诊断工作.
- 静脉注射免疫球蛋白 (IVIg) 治疗的使用.
- 监测患者对治疗的临床反应.
主要成果:
- 患者在IVIg治疗开始后出现了显著的临床改善.
- 这些改善表明对免疫调节治疗的积极反应.
结论:
- 这些发现支持了潜在的自身免疫过程,有助于患者的神经病变,红红色肌痛和胃肠异位症.
- 静脉注射免疫球蛋白疗法被证明是有效的,表明其作为类似复杂病例的治疗选择的潜力.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Myasthenia Gravis: Diagnostic Tests
890
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
890
Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143
Drugs for Treatment of Diarrhea-Predominant IBS
182
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
182
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
305
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
305


